The study is testing a new formulation of synthetic cannabidiol combined with the company’s novel Permetrex skin delivery technology.
Botanix Pharmaceuticals (ASX:BOT) is pleased to announce the treatment of the first patient in its Phase 1b BTX 1308 psoriasis patient study | ASX Announcement: https://t.co/paU854WOzO $BOT pic.twitter.com/2JIyDrLXAD— Botanix Pharma (@BotanixPharma) November 6, 2018
The phase 1b patient study is being conducted in collaboration with BioSkin GmbH, a German clinical contract research organisation and an Australian dermatology clinic.
Bioskin is internationally recognised for their experience with the psoriasis plaque test which is clinically validated and utilised by a number of leading dermatology companies.
The study is designed to assess the safety and efficacy of BTX 1308 on psoriasis plaques or lesions, with the ability to compare multiple formulations and test products at the same time, and on the same patient.
Botanix is advancing multiple clinical programs with near-term milestones
Botanix founder and executive director Matt Callahan said: “We are pleased to have enrolled and treated our first patient in the BTX 1308 psoriasis study.
“The unique design of this patient study which allows us to compare multiple drugs in the same patient at the same time, means that the treatment duration can be shortened, while the quality of data can also be enhanced.
“BTX 1308 is our third product to commence a patient study in the last 12 months, which demonstrates our ability to rapidly add new indications to the pipeline, as we can leverage the studies already successfully completed with synthetic cannabidiol in acne and atopic dermatitis.”